HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

Abstract
Based on exciting results in animal models, a number of novel immunotherapies employing biotechnological products, rather than conventional immunosuppressants, are being developed for the treatment of multiple sclerosis. The first part of this article is a review of some fundamental concepts of immunology and offers a hypothetical scenario for the immunopathogenesis of multiple sclerosis. The second part provides a critical overview of various immunotherapies relying on modern biotechnology. For each approach, the underlying immunological principles, experimental and clinical evidence, and foreseeable problems are separately addressed. Thus, it is hoped that this article serves a dual purpose, namely to provide an update on recent advances in immunology, and to serve as a useful source of reference to immunotherapies holding promise for future treatment of multiple sclerosis.
AuthorsR Hohlfeld
JournalBrain : a journal of neurology (Brain) Vol. 120 ( Pt 5) Pg. 865-916 (May 1997) ISSN: 0006-8950 [Print] England
PMID9183256 (Publication Type: Journal Article, Review)
Chemical References
  • Biological Products
Topics
  • Animals
  • Biological Products (therapeutic use)
  • Humans
  • Immunotherapy
  • Multiple Sclerosis (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: